Portfolio

Company Announcements

Issue of Equity

Related Companies

By LSE RNS

RNS Number : 1935R
Clinigen Group plc
19 September 2017
 

19 September 2017

 

Issue of Equity

Clinigen Group plc ("Clinigen" or the "Group", AIM: CLIN) announces that it has made an application for the admission to trading on AIM of 4,421 ordinary shares of 0.1 pence each in the Group (the "New Ordinary Shares"), which have been issued to satisfy the exercise of share options and rank pari passu with the existing shares of the Group. Admission to trading on AIM of the New Ordinary Shares is anticipated to occur at 8.00am on 20 September 2017.

 

At admission the issued share capital of the Group will consist of 115,165,344 ordinary shares, with no shares held in treasury. The total number of voting rights in the Group will therefore be 115,165,344.

 

Clinigen also announces today that it has applied for the admission of 44,742 ordinary shares of 0.1 pence each in the Group ("Shares") to trading on AIM.

 

These Shares were issued on the dates set out below pursuant to the exercise of share options by employees, but were not concurrently admitted to trading on AIM:

 

14,039 Shares on 21 October 2016

6,727 Shares on 2 November 2016

16,592 Shares on 5 January 2017

2,054 Shares on 13 January 2017

5,330 Shares on 17 May 2017

 

Admission of the Shares is expected to occur at 8.00am on 22 September 2017. There will be no change to the total issued share capital of the Company following admission of the Shares, which on admission of the New Ordinary Shares, will comprise 115,165,344 ordinary shares, with no shares held in treasury. This figure may be used by shareholders as the denominator to determine if they are required to notify their interests in, or a change to their interests in, the Group under the Disclosure Guidance and Transparency Rules.

 

-Ends-

 

Contact details

 

Clinigen Group plc

Tel: +44 (0) 1283 495010

Shaun Chilton, Group Chief Executive Officer


Martin Abell, Group Chief Financial Officer




Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black / Tom Ballard  (Corporate Broking)




RBC Capital Markets - Joint Broker

Tel: +44 (0) 20 7653 4000

Marcus Jackson / Elliot Thomas / Jack Wood




Instinctif Partners

Tel: +44 (0) 20 7457 2020

Melanie Toyne-Sewell / Alex Shaw

Email: clinigen@instinctif.com

 

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.

 

For more information, please visit www.clinigengroup.com 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOESFAFDUFWSELU

Top of Page